The study shows that the core component of Abera’s technology – Outer Membrane Vesicles (OMVs) – retains functional even after long-term storage, strengthening the platform’s potential for both stockpiling and cost-efficient vaccine production, the company states.

“Demonstrating that OMVs can be stored för longer time and at higher temperatures without losing functionality is a key milestone for us. It means we can produce and stockpile the platform’s carrier component in advance, which drastically shortens the timeline from an identified threat to a ready-to-use vaccine,” says Maria Alriksson, CEO of Abera Bioscience.

In the latest study, OMVs were stored in powder form at temperatures ranging from -20°C to +40°C for six months. The results show that OMVs retained their key properties in all cases – particularly the ability to bind antigens after storage – which is crucial for the platform’s intended use as a rapid and flexible base for vaccines in response to emerging infectious threats.

Collaboration with Orexo

The powder form of the OMVs was developed in collaboration with Orexo and is based on their AmorphOX technology.